Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 558.00
Ask: 560.00
Change: -2.00 (-0.36%)
Spread: 2.00 (0.358%)
Open: 548.00
High: 562.00
Low: 548.00
Prev. Close: 562.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Update

22 Feb 2023 07:00

RNS Number : 6201Q
Gooch & Housego PLC
22 February 2023
 

 

For immediate release

22 February 2023

 

Gooch & Housego PLC

("G&H", the "Group" or the "Company")

 

AGM Trading Update

 

"Significant progress made in adding productive capacity. Review of the Group's strategy progressing to plan. Trading in line with expectations."

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, will hold its Annual General Meeting at 11.00 a.m. today at the Company's headquarters in Ilminster, Somerset.

 

During the first four months of the financial year, the Group has made good progress in increasing its productive capacity as a result of our refocused recruitment and operational improvement activities. We are pleased to report that our UK production facilities are now fully resourced and, whilst we still have further roles to fill in some of our US facilities, the situation continues to improve. Our investment in inventory has helped protect our production programmes from persistent supply chain constraints. Consequently, the Group is making steady progress in lowering its lead-time for new orders received and reducing its overdue order book. The addition of productive capacity means that we now expect revenues to be more evenly balanced between the first and second halves of the financial year.

 

As previously reported, the Group continues to experience input cost inflation both in its employment costs and its supply chain. Whilst we are seeking to pass on these additional costs in our pricing, the size of the Group's order book means there will be some timing lag in this cost recovery. We, therefore, still expect inflation to have an impact on the Group's profitability in the current financial year.

 

Current year's trading continues to be in line with the Board's expectations.

 

As at 31 January 2023, our order book stood at £129.3 million (31 January 2022: £110.5 million), an increase of 17.0% compared with the same time last year but a reduction of 12.5% from the record level seen at the end of the previous financial year (30 September 2022: £147.7m). The improving levels of output have contributed to the order book reduction. We have also seen a moderation of order intake in parts of our Industrial and Life Science markets, with evidence of overstocking by some of our customers. Whilst we are alert to a potential market slow down, there remain multiple large value order opportunities for the Group's products and services that we expect to secure in the coming months and which will underpin expected revenues for FY2023 and beyond. 

 

The Group is refocusing investment into the development of earnings accretive new products with urgency to meet customer requirements. We are partnering with key customers in a number of areas including advanced semiconductor capacity expansion, directed energy systems, high power amplifiers for space communication and quantum based sensing, all of which are expected to provide the Group with profitable growth in the future.

 

Whilst we continue to invest in higher levels of inventory to protect our production programmes our receivables balance has reduced compared with the end of the previous financial year leading to a reduction in the Group's net debt position during the first four months of the financial year.

 

The review of the Group's strategy is progressing well and we expect to be able to provide more information at the time of the Group's interim results in June 2023.

 

 

Charlie Peppiatt, Chief Executive Officer of Gooch & Housego, commented:

 

"I am pleased with the initial progress in FY2023 from our initiatives to improve output, on-time delivery performance and lead times to meet customer expectations. We remain focused on further improvement across our production facilities as well as with our supply chain partners.

 

"There continues to be a significant level of positive technical interaction with our customers as we work with them on the development of their next generation photonics projects.

 

"The Group strategy review is progressing well and full year trading remains on track to meet the Board's expectations."

 

 

A slide deck to accompany the AGM can be viewed at the investor section of the Company's website, https://gandh.com/investors/

 

 

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / George Cleary

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA, Europe and China. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAMZGZZNMLGFZM
Date   Source Headline
1st Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Jun 20202:53 pmRNSDirector/PDMR Shareholding
2nd Jun 202011:37 amRNSDirector/PDMR Shareholding
2nd Jun 20207:00 amRNSInterim Results
18th May 20207:00 amRNSNotification of Half Year Results
11th May 20207:00 amRNSAppointment of Non-Executive Director
23rd Apr 20204:23 pmRNSHolding(s) in Company
9th Apr 20203:25 pmRNSHolding(s) in Company
7th Apr 20207:00 amRNSHalf Year Trading Update
27th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20204:42 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSUS Facilities Update
17th Mar 20201:22 pmRNSFremont Facility Update
16th Mar 20201:56 pmRNSDirector/PDMR Shareholding
6th Mar 20209:45 amRNSDirector Share Purchase
3rd Mar 20207:00 amRNSStreamlining of Manufacturing
19th Feb 202012:23 pmRNSResult of AGM
19th Feb 20207:00 amRNSAGM Trading Update
3rd Feb 202012:08 pmRNSIssue of Equity and Total Voting Rights
14th Jan 202010:21 amRNSGrant of LTIP Awards
27th Dec 20193:26 pmRNSDirectorate: David Bauernfeind
11th Dec 20197:00 amRNSPosting of Annual Report and AGM Notice
9th Dec 20198:50 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSPreliminary Results
20th Nov 20198:42 amRNSBlock listing Interim Review
15th Nov 20194:41 pmRNSSecond Price Monitoring Extn
15th Nov 20194:35 pmRNSPrice Monitoring Extension
11th Nov 201911:18 amRNSConfirmation of Directorate Change
8th Nov 201912:54 pmRNSTotal Voting Rights
7th Oct 20197:00 amRNSFull Year Trading Update and Results Notification
6th Aug 201912:02 pmRNSPrice Monitoring Extension
18th Jul 201910:11 amRNSChief Financial Officer Appointment Timing Update
1st Jul 201910:57 amRNSDirector/PDMR Shareholding
6th Jun 201912:58 pmRNSDirector Share Purchase
4th Jun 20194:23 pmRNSDirectors' Share Purchases
4th Jun 20197:00 amRNSDirectorate Change
4th Jun 20197:00 amRNSInterim Results
28th May 20199:52 amRNSHolding(s) in Company
9th May 20197:00 amRNSNotification of Half Year Results
30th Apr 20197:00 amRNSAppointment of Chief Financial Officer
9th Apr 20197:00 amRNSCapital Markets Day
9th Apr 20197:00 amRNSHalf Year Trading Update
28th Mar 20195:28 pmRNSDirector/PDMR Shareholding
28th Mar 20195:25 pmRNSDirector/PDMR Shareholding
28th Mar 20195:24 pmRNSDirector/PDMR Shareholding
25th Mar 20195:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSITL signs manufacturing agreement with OrganOx
25th Feb 201911:27 amRNSDirector Share Purchase
21st Feb 20192:58 pmRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.